Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 14/20 | 0.44 |
| ▸ | CA1 | P00915 | 13/20 | 0.44 |
| ▸ | CA12 | O43570 | 9/20 | 0.44 |
| ▸ | CA6 | P23280 | 8/20 | 0.44 |
| ▸ | CA7 | P43166 | 8/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 8/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | CA3 | P07451 | 3/20 | 0.42 |
| ▸ | CA4 | P22748 | 3/20 | 0.42 |
| ▸ | CA5A | P35218 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.42 |
| ▸ | CISD1 | Q9NZ45 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398831 | 0.87 | CA1 (0.49) | CA2CA1CA12CA6CA7 | |
| SCHEMBL2395680 | 0.85 | TRPV4 (0.44) | CA2CA1MEN1KMT2A | |
| SCHEMBL6269666 | 0.81 | CA2 (0.44) | CA2CA1CA12CA6CA7 | |
| SCHEMBL17151447 | 0.81 | CA2 (0.52) | CA2CA1CA12CA6CA7 | |
| SCHEMBL1804856 | 0.80 | PTGES2 (0.51) | CA2CA1CA12CA6CA7 | |
| SCHEMBL11740679 | 0.79 | ALDH1A1 (0.44) | CA2CA1CA12CA6CA7 | |
| SCHEMBL16822008 | 0.78 | KDM4E (0.56) | CA2CA1CA12CA6CA7 | |
| SCHEMBL1804853 | 0.78 | CA1 (0.46) | CA2CA1CA12CA6CA7 | |
| SCHEMBL12409433 | 0.78 | CA1 (0.48) | CA2CA1CA12CA6CA7 | |
| SCHEMBL7148985 | 0.78 | CA2 (0.70) | CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017608-B2 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2011-09-13 | — | — | US | disclosed |
| EP-1608647-B1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | NOVARTIS AG (CH) | 2006-07-06 | — | — | US | disclosed |
| EP-1608647-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | Novartis AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004078754-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148822-A1 | 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors | MAP3K13, AKT3, MAP3K3 | CA2 2321/4885CA1 4444/4885CA12 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.